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Background: People with T1DM and insulin-treated T2DM often do not follow and/or adjust their insulin regimens
as needed. Key contributors to treatment non-adherence are fear of hypoglycaemia, difficulty and lack of
self-efficacy associated with insulin dose determination. Because manual calculation of insulin boluses is both
complex and time consuming, people may rely on empirical estimates, which can result in persistent
hypoglycaemia and/or hyperglycaemia. Use of automated bolus advisors (BA) has been shown to help insulin
pump users to more accurately meet prandial insulin dosage requirements, improve postprandial glycaemic
excursions, and achieve optimal glycaemic control with an increased time within optimal range. Use of a BA
containing an early algorithm based on sliding scales for insulin dosing has also been shown to improve HbA1c
levels in people treated with multiple daily insulin injections (MDI). We designed a study to determine if use of an
automated BA can improve clinical and psychosocial outcomes in people treated with MDI.
Methods/design: The Automated Bolus Advisor Control and Usability Study (ABACUS) is a 6-month, prospective,
randomised, multi-centre, multi-national trial to determine if automated BA use improves glycaemic control as
measured by a change in HbA1c in people using MDI with elevated HbA1c levels (>7.5%). A total of 226 T1DM and
T2DM participants will be recruited. Anticipated attrition of 20% will yield a sample size of 90 participants, which
will provide >80% power to detect a mean difference of 0.5%, with SD of 0.9%, using a one-sided 5% t-test, with
5% significance level. Other measures of glycaemic control, self-care behaviours and psychosocial issues will also be
assessed.
Discussion: It is critical that healthcare providers utilise available technologies that both facilitate effective glucose
management and address concerns about safety and lifestyle. Automated BAs may help people using MDI to
manage their diabetes more effectively and minimise the risk of long-term diabetes related complications. Findings
from a recent study suggest that BA use positively addresses both safety and lifestyle concerns; however,
randomised trials are needed to confirm these perceptions and determine whether bolus advisor use improves
clinical outcomes. Our study is designed to make these assessments.
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Large clinical trials have shown that intensive manage-
ment of glycaemia and other vascular risk factors can
prevent or delay the development of microvascular and
macrovascular complications in both type 1 diabetes
(T1DM) and type 2 diabetes (T2DM) [1-4]. Achieving
optimal glycaemic control in people with T1DM [1,2]
and advanced T2DM [5] often requires intensive insulin
therapy, which involves either use of insulin pumps or
multiple daily insulin injections (MDI) [1,2,5]. Such ther-
apies divide insulin doses into basal, prandial and cor-
rective elements, which can be adjusted independently
to achieve optimal results. Despite the benefits of inten-
sive diabetes management, many people with T1DM and
insulin-treated T2DM do not follow and/or adjust their
insulin regimens as needed [6-9]. A recent survey of 331
people with T1DM showed that 64% of the participants
assessed their prandial insulin need inappropriately [10].
A significant obstacle to intensive insulin manage-
ment is fear of hypoglycaemia [11-14], which has det-
rimental effects on people’s willingness to effectively
manage their diabetes, particularly in terms of appro-
priate insulin dosing (e.g., under-dosing of insulin to
avoid hypoglycaemia). This can lead to poor metabolic
control and subsequent poor health outcomes [14].
Other key contributors to treatment non-adherence
are lack of self-efficacy and difficulties associated with
insulin dose determination. Calculation of an insulin
dose is a complex process that must take numerous
factors into account, such as the current preprandial
glucose level, grams of carbohydrate (CHO) to be
ingested, insulin sensitivity, insulin-to-CHO ratio, and
active insulin on board. Further, poor glycaemic con-
trol has been correlated with poor numeracy skills
[15]. This may lead to an inability to count carbohy-
drates, errors in interpreting blood glucose (bG) results
to determine correction doses and inaccuracies in cal-
culating insulin doses based on insulin-to-CHO ratios.
Although many insulin pumps now feature automated
bolus advisors, which automatically calculate bolus insulin
dosages to cover carbohydrate (CHO) intake and address
out-of-range bG levels based on individualised insulin par-
ameter estimates, people using MDI therapy must perform
these dosage calculations manually. However, because
manual calculation of insulin boluses is both complex and
time consuming, people may rely on empirical estimates,
which can result in persistent hypoglycaemia and/or
hyperglycaemia [16,17]. In addition, manual bolus calcula-
tion does not take into account the effect of the active
insulin that remains from the initial bolus (insulin-
on-board), which creates a high potential for errors,
particularly when determining a correction bolus.
Studies have demonstrated that use of automated bolus
calculators helps insulin pump users more accuratelymeet prandial insulin dosage requirements, improve
postprandial glycaemic excursions, and achieve optimal
glycaemic control with an increased time within target
range [18,19]. It is, indeed, possible that such automated
calculations may be a major source of the perceived ben-
efits of pump therapy for many patients. For example, a
study by Garg and colleagues [20] showed that use of a
bolus advisor containing an early algorithm based on
sliding scales for insulin dosing in people using MDI
resulted in improved HbA1c levels. Results from a recent
survey [21] suggest that use of an automated bolus ad-
visor may reduce fear of hypoglycaemia, increase confi-
dence in bolus calculation, improve ability to control bG
levels and achieve glycaemic goals, create a sense of
increased flexibility in lifestyle, and improve overall well
being. In a small pilot study, Schmidt and colleagues [22]
found that automated bolus advisor use, in conjunction
with training in CHO counting and MDI therapy,
improves treatment satisfaction. However, to date, no
large randomised trials have been conducted to deter-
mine whether use of an automated bolus advisor can im-
prove glycaemic control and promote greater adherence
to therapy in people treated with MDI therapy.
We hypothesised that, in addition to reducing
HbA1c, use of an automated bolus advisor in people
treated with MDI therapy can increase the time bG
stays within the target range, reduce the magnitude of
post-prandial excursions, reduce the frequency/severity
of hypoglycaemia, and improve psychosocial outcomes,
including treatment satisfaction, social functioning and
factors important to quality of life. We designed a
study to test this hypothesis, using a new automated
bolus advisor system that integrates bolus calculation
into a bG meter.
Methods/design
The Automated Bolus Advisor Control and Usability
Study (ABACUS) is a 6-month, multi-center, multi-na-
tional, prospective, randomised, controlled study to as-
sess the impact of automated bolus advisor use on
clinical and psychosocial outcomes in poorly controlled
(>7.5% HbA1c), MDI-treated T1DM and T2DM partici-
pants. The trial will be conducted at approximately 30
sites in the UK and Germany. All sites will have prior
experience working with the bolus advisor prior to study
initiation. All clinical investigators from the sites
involved will be given detailed educational input regard-
ing the device settings and adjustment principles (either
using the automated bolus advisor or using more trad-
itional ‘paper-copy’ (e.g., insulin-to-carbohydrate ratio/
insulin sensitivity factor) at centralised study training
sessions. The study protocol was approved by the Na-
tional Research Ethics Service (Redditch, UK) and Ethik-
Kommission der Ärztekammer Westfalen-Lippe und der
Table 1 Inclusion and exclusion criteria
Inclusion Criteria:
• Must be 18 years of age or older
• Diagnosed with Type 1 or Type 2 diabetes
• Recent HbA1c >7.5% (measured within the last 6 weeks at local
laboratory)
• Using MDI therapy for at least 6 months consisting of 1–2 injections
per day of long-acting basal insulin (Lantus® or Detemir®) and at
least 2 injections per day of regular or rapid-acting analog insulin for
meal coverage
• Participant adjusts meal insulin doses based on carbohydrate
content of meals
• Participant with Type 2 diabetes may be on stable metformin therapy
(therapy unchanged during 3 months prior to study)
• Participant has been in Investigator's practice for at least 3 months;
however may have been seen by another physician in the practice
• Participant has completed carbohydrate (CHO) training within
the last 2 years
Exclusion Criteria:
• On a therapy regimen that conflicts with study:
• NPH or pre-mixed insulin
• Oral anti-diabetic agents, with the exception of metformin
• Injectable anti-diabetic agents other than long-acting insulin and
rapid-acting insulin analogs or regular insulin
(e.g., fixed dose therapy)
• Use of sliding scale insulin therapy that determines insulin dosages
based exclusively on specific bG results
• Participated in another interventional trial within 6 weeks
prior to study
• Diagnosed with any clinically significant infectious disease or
major organ system disease, such as gastroparesis or renal disease
(at Investigator's discretion)
• Used systemic oral or inhaled steroids for more than 7 days within
the last 3 months
• On Chemotherapy or Radiation therapy (self-reported)
• Pregnant or lactating or is currently planning a pregnancy
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Universität Münster (Münster, Germany) and is in com-
pliance with the Helsinki Declaration [23].
The primary outcome of the study is to determine if
use of an automated bolus advisor is associated with a
significant reduction in HbA1c over 6 months, com-
pared with a group having the same diabetes educational
background but with no access to an automated bolus
advisor. The goal is to decrease HbA1c by >0.5%. Sec-
ondary outcomes include: 1) change in time spent within
bG target range; 2) frequency and severity of
hypoglycaemia; 3) change in magnitude of postprandial
glucose excursions; 4) change in glycaemic variability
parameters; 5) frequency of bolus advisor use; 6) fre-
quency of participants’ adjustments to proposed bolus
amounts; 7) self-monitoring of blood glucose (SMBG)
test frequency; 8) change in participants’ therapy adher-
ence and use of rule sets; and 9) participant self-care
behaviours, and psychosocial outcomes including treat-
ment satisfaction, social functioning and factors import-
ant to quality of life.
Participants
The study will recruit 226 T1DM and T2DM patients
who have been using MDI therapy for at least 6 months.
Participants will be enrolled and randomised to the ex-
perimental (EXP) or control (CNL) groups; 113 partici-
pants in each group. This will lead to a total of 90
participants completing each arm at 6 months, assuming
a drop-out rate of 20%.
Key inclusion criteria are: ≥18 years of age; T1DM or
T2DM treated with MDI therapy for ≥6 months; HbA1c
>7.5%; adjusts meal insulin doses based on CHO content
of meal; and has completed CHO training within last 2
years. Key exclusion criteria are: NPH or pre-mixed in-
sulin; treated with anti-diabetic agents (except metfor-
min); use of fixed-dose therapy; or use of sliding scale
insulin doses determined exclusively on specific bG
results. The complete list of inclusion and exclusion cri-
teria is presented in Table 1.
Participants will be identified and recruited from the
investigators’ established patient population or from
within the patient population of other physicians within
their group practice using the inclusion/exclusion cri-
teria. Participants who agree to take part in the study
and meet all of the inclusion but none of the exclusion
criteria will be asked to sign the approved Informed
Consent Form for the study.
Design
Participants will be randomised (1:1) by participant code
number to a control group (CNL) or to bolus advisor
use (EXP) where they will utilise an automated bolus ad-
visor to determine prandial and correction insulin doses.Both study groups will receive intensive diabetes man-
agement with frequent assessment and adjustment of in-
sulin therapy parameters. The study design is shown in
Figure 1. Participants from both arms will be evaluated
with the same scales and measures at the same time
intervals over 6 months.
Procedure
EXP participants will utilise the Accu-Chek® Aviva
(Roche Diagnostics, Indianapolis, USA), which incorpo-
rates an automated bolus advisor into a blood glucose
meter. Users can obtain prandial and correction bolus
recommendations based upon a current blood glucose
value, planned carbohydrate intake and individualised
therapy parameters stored in the device. The device
automatically calculates the appropriate bolus for the









Figure 1 CONSORT Diagram.
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the automated bolus advisor device can assist people in
achieving desired postprandial glucose control without
significant hypoglycaemia.
Physicians and staff in both arms will be informed about
the clinical investigational plan, including the rationale for
the study, design of the study protocol, subject-related
procedures, and use of evaluation questionnaires. EXP
physicians and staff will receive training on using the auto-
mated bolus advisor device to set insulin parameters and
download SMBG and insulin dosing data.
Approximately 50-60% of the sites (those with prior ex-
perience of CGM use) will utilise a blinded continuous
glucose monitoring (CGM) device (DexCom Seven® Plus,
DexCom, Inc., San Diego, California, USA), with data
uploaded directly to a designated secure server. Clinicians
and participants will not have access to this CGM data for
the duration of the study, which will be analysed centrally
to contribute to the secondary end-points of the study.
Visit schedule
The 6-month study will consist of a screening and train-
ing period of approximately 2 weeks ± 5 days and an
intervention period of approximately 24 weeks. An op-
tional follow-up patient survey by the investigator will
be administered after an additional 26 weeks following
Visit 10 (End of Study) (Figure 2).
Visit 1: screening and training (week – minus 2)
At Visit 1, investigators will confirm participants’ eligibil-
ity for the study (based on inclusion/exclusion criteria),
obtain written informed consent, record demographic
information, collect relevant medical history/lifestyle in-
formation, document all current medications, perform
physical examinations, measure and record weight,
height, blood pressure, heart rate, collect blood and
urine samples for laboratory tests (HbA1c, urinalysis,
chemistry panel with lipids, full blood count [FBC]) and
perform pregnancy testing (for women of child bearing
age). Participants will be asked to complete a question-
naire that incorporates the questions from standard psy-
chometric instruments (See Measures section).Investigators will use standardised worksheets to as-
sess participants’ knowledge and skills relevant to MDI
therapy and CHO counting. Selected Dose Adjustment
For Normal Eating (DAFNE) plates will also be used in
the CHO counting assessment. Deficits in MDI therapy
and CHO counting skills will be documented and
addressed during Visit 2.
Participants in both groups will initially receive a
blood glucose meter (Accu-Chek® Nano blood glucose
meter, Roche Diagnostics, Indianapolis, Indiana, USA)
and will be thoroughly trained in its operation. Where
applicable, investigators will connect the CGM device to
subjects and provide training.
Participants will be instructed to generate 7-point gly-
caemic profiles (preprandial/2-hours postprandial at all
meals, and bedtime) over 3 consecutive days and docu-
ment their results on a standardised form that will be
provided. Using the form, participants will also docu-
ment details of their meals (including number of CHOs),
physical exercise (intensity and duration), basal insulin
doses, prandial bolus doses, and correction bolus doses
over the 3-day testing period. CGM participants will be
instructed to wear their device until Visit 2. This will be
done in addition to completing their 3-day, 7-point gly-
caemic profiles.
Visit 2: randomisation and intensive monitoring
(week – minus 1)
At Visit 2, investigators will collect participants’ bG
meters, completed 3-day glycaemic profiles and CGM
devices (if applicable). Investigators will upload bG
meter data via the research version of the Accu-Chek®
SmartPix device (Roche Diagnostics, Indianapolis, Indi-
ana, USA). When applicable, CGM data will also be
uploaded to the server. Blood glucose data will be
downloaded to clinic software, using either the com-
mercial Accu-Chek® Smart Pix device or Accu-Chek®
360˚ View diabetes management system software
(Roche Diagnostics, Indianapolis, Indiana, USA), and
investigators will prepare printouts to review with
each participant. New adverse events (AEs) and sig-
nificant adverse events (SAEs), or changes in ongoing
AEs/SAEs since the last visit, will be assessed and
recorded; participants’ concomitant medications will be
updated.
Investigators will then conduct MDI and CHO
counting training, which will be individualised to ad-
dress each participant’s knowledge and/or skills deficits
as identified during the MDI therapy and CHO count-
ing assessments performed at Visit 1. Standardised
checklists will be used to document participant compe-
tencies. Participants must be competent in both MDI
therapy and CHO counting knowledge in order to con-
























• Administer Subject Questionnaire
• Assess MDI/CHO Counting capabilities
• Connect CGM device
• Upload SMBG and CGM data
• Collect/Review 3-day profiles 
• Conduct MDI/CHO Counting training
• Randomize subjects
Information about concomitant medications and AEs / SAEs collected at each visit
• Upload SMBG and CGM data
• Establish therapy parameters
• Train EXP subjects on BA device
• Review/adjust therapy parameters
• Upload SMBG and CGM data
• Collect/Review 3-day profiles 
• Review/adjust therapy parameters
• HbA1c/lab tests
• Connect CGM device
• Upload SMBG and CGM data
• Collect/Review 3-day profiles 
• Review/adjust therapy parameters
• Administer Subject Questionnaire 
(except DTSQc)
• Connect CGM device
• Upload SMBG and CGM data
• Collect/Review 3-day profiles
• Review/adjust therapy parameters
• Labs
• Administer Subject Questionnaire      
(with DTSQc
• Upload SMBG and CGM data
Figure 2 Study Visit Schedule.
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usual care or to bolus advisor use (EXP). EXP partici-
pants will be given automated bolus advisor training
materials for review at home.
Visit 3: training and therapy initiation (week – 0)
At Visit 3, investigators will collect participants’ bG
meters, upload bG meter data to the secure server;
download meter data to clinic software, and prepare
printouts of bG data to review with participants. New
AE/SAEs or changes to ongoing AE/SAEs since the last
visit will be assessed and concomitant medications
updated. Investigators will use the therapy parameter
cards and instruct participants on how to use their
parameters.EXP participants will be given their automated bolus
advisor device (Accu-Chek® Aviva Expert bG meter,
Roche Diagnostics, Indianapolis, Indiana, USA) and
instructed to discontinue use of their current bG meter.
Investigators will conduct 1-hour training sessions in
automated bolus advisor device use and update the
devices with each participant’s new therapy parameters.
At the conclusion of the visit, all participants will re-
ceive SMBG supplies and a logbook with a 3-day gly-
caemic profile form. Participants will be instructed to
complete the 3-day profiles one week prior to Visit 5.
Visit 4: telephone follow-up (week – 2)
Investigators will have the option to conduct Visit 4 as
either a clinic visit or via telephone. New AE/SAEs or
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assessed, concomitant medications updated, and therapy
parameters will be adjusted as needed. Investigators will
schedule the next visit (Visit 5) and remind participants
to complete their 3-day glycaemic profile prior to that
visit.
Visits 5 through 9 (weeks – 4 through 24)
At Visits 5 through 9, investigators will collect partici-
pants’ bG meters, upload bG meter data to a secure ser-
ver; download meters to clinic software, and prepare
printouts of bG data to review with participants. New
AE/SAEs or changes to ongoing AE/SAEs since the last
visit will be assessed and concomitant medications will
be updated. At Visits 5, 7 and 9, participants’ 3-day gly-
caemic profiles and historic data will be collected and
reviewed to adjust therapy parameters (if needed). If
parameters are adjusted, participants’ automated bolus
advisor devices will be updated with the new parameters.
HbA1c samples will be collected at Visits 6 and 9. Add-
itional laboratory samples will be obtained at Visit 9 for
chemistry profile and lipid profile, FBC, perform dipstick
urinalysis. At Visits 7 and 9, 5-day CGM data will
be uploaded to the secure server. Patient questionnaires
will be administered at Visits 7 and 9. Final CHO count-
ing and MDI therapy assessments will be conducted at
Visit 9.
Visit 10: telephone follow-up (week – 24 +48 hours)
At Visit 10, investigators will call each participant 48
hours after Visit 9 to assess and record new AE/SAEs or
changes to ongoing AE/SAEs since their last visit.
Optional follow-up (26 weeks after Visit 10)
Investigators have the option to schedule an additional
clinic visit approximately 26 weeks after Visit 10 to ob-
tain participants’ most recent HbA1c value (performed
locally as part of routine practice) and collect informa-
tion about participants’ use of the automated bolus ad-
visor device. This would include downloading data from
the automated bolus advisor and documenting partici-
pants’ current insulin parameters.
Measures
Primary endpoint
HbA1c: The primary endpoint of the study is glycaemic
control, as assessed by change in HbA1c from baseline
over 6 months specifically, looking at number of patients
who achieved >0.5% HbA1c reduction at study end.
Blood samples will be collected at screening and Visits 6
(week 11) and 9 (week 24). HbA1c analysis will be con-
ducted by a central laboratory, using HPLC methodology
(VII Turbo haemoglobin testing system, Bio-Rad La-
boratories, Hercules, California, USA).Secondary endpoints
Time within Target Range: CGM data (from 50-60% of
participants) will be used to assess the change in time
spent within the target bG range of 72–180 mg/dl from
baseline to study end. CGM data will be collected at Vis-
its 2 (week minus 1), 7 (week 12), and 9 (week 24).
Other Glycaemic Measures: Glucose data from 3-day
glycaemic profiles, derived from uploaded SMBG and
CGM data (when applicable) will be used to assess: 1)
frequency of hypoglycaemia (within 50–72 mg/dl) and
severe hypoglycaemia (<50 mg/dl with associated symp-
toms), overall, and by defined time blocks (12:00 a.m. to
5:00 a.m., 5:00 a.m. to 10:30 a.m., 10:30 a.m. to 4:30 p.
m., 4:30 p.m. to 12:00 a.m.); 2) total number of SMBG
tests and average number of SMBG tests per day and by
the defined time blocks; 3) percentage of all values, pre-
prandial values (60–0 minutes prior to meal) and post-
prandial values (60–180minutes after start of meal)
within defined bG ranges (<50 mg/dl, 50–72 mg/dl, 72–
180 mg/dl, 180–300 mg/dl, >300 mg/dl); 4) mean bG
across the 3-day profiles and for each of the 7 time
points; 5) standard deviation (SD) and coefficient of vari-
ation across the 3-day profiles; 6) Mean and SD differ-
ences between preprandial and postprandial bG values
over each meal in the 3-day profiles; 7) mean amplitude
of glycaemic excursions (MAGE), low bG index (LBGI),
high bG index (HBGI), bG risk index (BGRI) and risk
for hypoglycaemia and hyperglycaemia across the 3-day
profiles. The 3-day glycaemic profile data will be col-
lected at Visits 2 (week minus 2), 5 (week 4), 7 (week
12) and 9 (week 24).
Automated Bolus Advisor Use and Participants’
Adjustments (EXP Group): The frequency of participants’
bolus advisor use and subsequent adjustments based
on proposed bolus amounts will be derived from data
uploads of the automated bolus advisor device. Ana-
lyses will include: average number of times per day
participants sought advice for mealtime and correction
bolus calculation; average number of times per day
participants accepted the automated bolus advisor ad-
vice; average number of insulin doses adjusted up or
down per day; average number of times participants
accepted the automated bolus advisor responses and
adjusted boluses within specific time periods (a.m.,
p.m., after 10 p.m.); and differences between the aver-
age number of adjusted mealtime boluses and adjusted
correction boluses.
Participant Adherence/Use of Rule Sets: Changes in
participants’ therapy adherence to and use of rule sets in
EXP participants will be derived from downloaded data
obtained from automated bolus advisor devices. Adher-
ence in CNL participants will be derived from documen-
ted therapy parameters and participants’ diaries, which
are included in 3-day glycaemic profile forms. These
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herence/use of rule sets correlates with improvement in
glycaemic control. Analyses will include: average number
of correctly and incorrectly used insulin-to-carbohydrate
(I:CHO) rules per day for CHO intake; average number
of correctly and incorrectly used insulin sensitivity factor
(ISF) rules per day for bG adjustment; and number of
changed I:CHO and ISF parameters compared to ther-
apy parameters at study start (Visit 3). Data will be col-
lected at Visits 2 (week minus 2), 5 (week 4), 7 (week
12) and 9 (week 24).
CHO Counting: Changes from baseline in participants’
ability to accurately count CHO will be assessed using
the DAFNE plate assessment scores from Visit 1 (week
minus 2) and 9 (week 24). This assessment will be used
to determine if participants’ CHO counting skills corre-
lates with improvement in glycaemic control.
Psychosocial Outcomes: Psychosocial outcomes includ-
ing treatment satisfaction, social functioning and factors
important to quality of life will be assessed using the
participant questionnaire, which incorporates questions
from validated psychometric instruments, as well as
commonly used survey questions, to assess depression,
diabetes-specific distress, diabetes self-efficacy, treatment
satisfaction, health outcomes and fear of hypoglycaemia.
Participant questionnaire items include: Patient Health
Questionnaire depression scale (PHQ-8) [25]; Problem
Area in Diabetes (PAID) [26]; Hypoglycaemia Fear ScaleTable 2 Participant Questionnaire components
Instrument Description
Patient Health Questionnaire 8
(PHQ-8) [25]
Self-report measure of depression
Problem Area in Diabetes (PAID) [26] Covers a range of emotional states
reported in diabetes. It is primarily a
of diabetes-specific emotional distre
HFS II (Hypoglycaemia Fear Scale) [11] Provides an assessment of an indivi
of hypoglycaemia both overall and
of behaviour and worry. IUsed to as




and DTSQc (change) [27]
Baseline version measures patient s
with diabetes treatment Change ve
developed to overcome ceiling effe
treatment satisfaction
Gold Scale [28] Categorises awareness of having re
awareness of hypoglycaemia in pat
with diabetes.
EuroQol-5 Dimensions-5
Levels measure (EQ-5D-5L) [29]
Measures health outcomes and is a
to a wide range of health condition
treatments(HFS –II) [11];Diabetes Treatment Satisfaction Question-
naire (DTSQs, [baseline] and DTSQc [change]) [27];Gold
Scale [28];and EuroQol-5 Dimensions-5 Levels measure
(EQ-5D-5L) [29] (Table 2). The questionnaires will be
administered at Visits 1 (week minus 2), 7 (week 12) and
9 (week 24); however, the DTSQs and DTSQc portions
will be administered only at Visits 1 and 9.
All scales and measures used in the study will contain
participant codes rather than participant identifiers. Par-




The Intent to Treat (ITT) population is defined as all
eligible participants who participated in Visit 1 (screen-
ing) and Visit 2 (randomisation); all efficacy and safety
analyses will be performed on this population. The per
protocol population (PP) will include all participants of
the ITT group who completed all scheduled visits with-
out any major protocol deviations. Participants must
complete at least 80% of all bG measurements of the 3-
day glycaemic profile form to be included in the PP
analysis.
Primary outcome analysis
Anticipated attrition of 20% will yield a sample size of
180 (90 per study group), which will provide >80%Scoring
Each of 8 items scores from 0=‘not at all’
to 3=‘nearly every day’ Major depressive
disorder (PHQ-8): ≤ 4 – no significant symptoms,
5 to 9 – mild symptoms, 10 to 14 – moderate
symptoms, 15 to 19 – moderately severe symptoms,




Each of 20 items scores from 0=‘not a problem’
to 4=‘serious problem’ PAID summary score:
0 to 39 – no distress, 40 to 59 – mild distress 60 to 79 –





Each of 33 items scores from 0=‘never’ to 4=‘always’
Score for frequency/severity of avoidance behaviour:
0 to 36 – no/slight avoidance behaviour: 37 to 48 –
moderate avoidance behaviour: 49 to 60 – frequent/
severe avoidance behaviour Score for severity of worry:
0 to 43 – no/slight worry: 44 to 57 – moderate worry:




DTSQs – Each of 6 items scores from 0=‘very bad’ to
6=‘very good’ DTSQc – Each of 6 items scores
from −3=‘much worse now’ to 3=‘much better now’)
duced
ients
One item with score from 1=‘always aware’ to 7=‘never
aware’ Impaired awareness if the Gold scale score is ≥4
pplicable
s and
Each of the 5 items score from 1=‘no problems’ to
5=‘unable’) EQ-5D health assessment scores from 0=‘worst
health’ to 100=‘best health’)
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HbA1c, with SD of 0.9%. The absolute and relative
change in HbA1c from baseline to study end for the
CNL and EXP groups will compared using the two-
sample t-test for the pooled ITT population. These tests
will be performed at the one-sided 5% level of signifi-
cance for rejecting the null hypothesis of no difference
or a difference in favor of the CNL group. An analysis of
covariance with the binary covariables (study group, sex
and diabetes type) and the continuous baseline covari-
ables (HbA1c, age and CHO counting assessment score)
will be performed for the absolute and relative HbA1c
change. Additional separate analyses of (co)variance will
be performed using two explanatory variables (study
group and one adjusting covariable) for the above men-
tioned covariables and other baseline covariables (e.g.,
country, center, time since diabetes diagnosis, existing
diabetes related diseases, time since MDI start, bG
measures from SMBG at baseline, frequencies of
hypoglycaemia at baseline, laboratory parameters and,
summary scores from psychosocial questionnaires) for
the pooled groups. The one-sided 95% confidence
intervals of the HbA1c change for CNL and EXP
groups and the difference between the groups will also
be calculated for the pooled groups.
Summary statistics (N, mean, median, SD, lower and
upper quartile, minimum and maximum) will be pro-
vided for the observed HbA1c values by study group for
each applicable scheduled visit (Visits 1, 6 and 9).
Graphical techniques will be used to display the HbA1c
change over time.
Pearson correlation coefficients will be computed for
the HbA1c values at Visits 1, 6, and 9 and the abso-
lute and relative HbA1c changes from baseline to
study end vs. demographic and clinical variables; bG
measures from SMBG and CGM scores for each col-
lection visit, other laboratory parameters, frequencies
of hypoglycaemia, CHO scores; and summary scores
from psychosocial questionnaires. For all of these cov-
ariables, the correlation coefficients for their changes
from baseline vs. the HbA1c parameters will be com-
puted, too. Additionally, the correlation coefficients for
the HbA1c parameters vs. bolus advisor parameters
will be computed for the EXP group.
Secondary outcome analyses
Statistical analysis of change in time spent within tar-
get range will be performed according to the same
schemata used for the primary outcome. Other sec-
ondary outcome variables will be compared descrip-
tively by study groups for each scheduled visit and for
changes between visits. Continuous variables, including
scores from the questionnaires will be summarised
using N, mean, SD, median, lower and upper quartile,minimum and maximum; categorical variables will be
summarised using counts and percentages of partici-
pants in each category. Two-sample t-tests in the case
of continuous variables and chi-square tests in the case
of categorical variables will be performed for group
comparisons. Graphical techniques will be used to dis-
play changes over time, if appropriate. Pearson correl-
ation coefficients will be computed between all
variables of interest.
Discussion
Optimal diabetes management is not achieved by many
people with T1DM or insulin-treated T2DM who do not
adjust their insulin regimens as needed [6-9]. This can
lead to poor metabolic control and subsequent poor
health outcomes [14]. Inadequate management of gly-
caemia within this population is complex and often the
result of many factors, including: fear of hypoglycaemia
[11-14]; lack of self-efficacy and difficulty with insulin
dose adjustment; and poor numeracy skills [15].
Many of today’s insulin pump systems now feature
automated bolus advisor technology, which calculates
individualised bolus insulin dosages to cover carbohy-
drate (CHO) intake and address out-of-range bG levels.
Studies have shown that use of automated bolus advisor
technology among insulin pump users facilitates accur-
ate determination of prandial insulin dosages, reduces
postprandial excursion, and reduces hypoglycaemia,
leading to improved glycaemic control [18,19].
Our study is designed to assess the impact of auto-
mated bolus advisor use on glycaemic control, user ad-
herence, self-care behaviours, treatment satisfaction,
social functioning and factors important to quality of
life. A potential limiation of our study design is the in-
tensity of diabetes management provided to both
groups, which may lead to significant improvements in
all participants and, thus, limit between-group differ-
ences. A third, “pure” control arm (no intervention)
would have been ideal to compare the intervention
with real-world clinical care; however, this option was
not feasible.
Given the benefits of tight metabolic control, it is
critical that healthcare providers utilise available tech-
nologies that not only facilitate effective glucose man-
agement but also address concerns about safety and
lifestyle, which can discourage adherence to therapy.
Although a growing body of evidence suggests that
automated bolus advisor use positively addresses safety
and lifestyle concerns [21,22], large, randomised trials
are needed to confirm these findings and assess the
utility of automated bolus advisor use in improving
intra-day and long-term glycaemic control. Our study
is designed to make these assessments. Findings will
be available in late 2012.
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